Management of hepatocellular carcinoma in the elderly.

摘要: Mean age of hepatocellular carcinoma (HCC) patients has been progressively increasing over the last decades and ageing these is becoming a real challenge in every day clinical practice. Unfortunately, international guidelines on HCC management do not address this problem exhaustively provide any specific recommendation. We carried out literature search MEDLINE database for studies reporting epidemiology, characteristics treatment outcome elderly patients. Available data seem to indicate that mostly influenced by liver function tumor stage rather than latter should influence allocation. Age risk resection older with resectable good could gain benefit from surgery. Mild comorbidities contraindication surgery aged Conversely, major elderly, even when performed experienced high-volume centres, be avoided. Both percutaneous ablation transarterial chemoembolization are contraindicated safety profile procedures acceptable. Sorafenib viable option advanced provided careful evaluation concomitant comorbidities, particularly cardiovascular ones, taken into account. suggest either younger, main predictor outcome. Consequently, nihilistic attitude physicians towards under- or no-treatment longer justified.